India, March 7 -- Alembic Pharmaceuticals announced that United States Food and Drug Administration (USFDA) has conducted an inspection at its Bioequivalence Facility located at Vadodara from 3r March 2025 to 7 March 2025. This was a scheduled inspection. The USFDA issued a Form 483 with one procedural observation.
Published by HT Digital Content Services with permission from Pivotal Sources....